Study Highlighting ENDRA Life Sciences’ TAEUS Technology to be Presented at EASL International Liver Congress 2023
2023年6月7日 - 9:00PM
ビジネスワイヤ(英語)
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo
Acoustic Enhanced UltraSound (TAEUS®), today announced the
acceptance of a poster titled “Thermoacoustic assessment of fatty
liver disease - an early clinical feasibility study” for
presentation at the International Liver Congress™ 2023 hosted by
the European Association for the Study of the Liver (EASL), taking
place June 21-24 in Vienna, Austria.
“This presentation highlights the correlation between TAEUS
measurements to the gold standard MRI-PDFF, and we are pleased this
poster was accepted by Europe’s most prestigious liver conference.
This small study was conducted prior to the implementation of our
current software guidance tool that is designed to improve
intra-operator consistency, yet the data make a compelling case of
TAEUS’ potential to assess fatty liver disease non-invasively,”
stated Michael Thornton, Chief Technology Officer of ENDRA. “This
peer-reviewed abstract is the first of what we expect to be several
presentations at scientific and medical conferences to document the
TAEUS system’s capabilities. We look forward to continuing to
publish and demonstrate the benefits of TAEUS among healthcare
professionals.”
Abstract Number: 3381 Title: Thermoacoustic
assessment of fatty liver disease - an early clinical feasibility
study Presenter: Michael Thornton Session: NAFLD:
Experimental and pathophysiology Date: June 21, 2023
Time: 9:00am – 6:00pm Central European Time
The poster will be available on the Research and Media section
of ENDRA's website after the conference ends.
ENDRA will be showcasing its TAEUS technology with
demonstrations at EASL in booth #E12.
About ENDRA Life Sciences Inc. ENDRA Life Sciences is the
pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a
ground-breaking technology being developed to visualize tissue like
MRI, but at 1/50th the cost and at the point of patient care.
TAEUS® is designed to work in concert with the more than 700,000
ultrasound systems in use globally today. TAEUS® is initially
focused on the measurement of fat in the liver as a means to assess
and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and
Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that
affect over two billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements All statements in this press
release that are not based on historical fact are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can
generally be identified by the use of terms such as “approximate,”
"anticipate," “attempt,” "believe," "could," "estimate," "expect,"
“forecast,” “future,” "goal," “hope,” "intend," "may," "plan,"
“possible,” “potential,” “project,” "seek," "should," "will,"
“would,” or other comparable terms (including the negative of any
of the foregoing), although some forward-looking statements are
expressed differently. Examples of forward-looking statements for
ENDRA include, among others: estimates of the timing of future
events and anticipated results of our development efforts,
including the timing of submission for and receipt of required
regulatory approvals and product launches; statements relating to
future financial position and projected costs and revenue;
expectations concerning ENDRA's business strategy; and statements
regarding ENDRA’s ability to find and maintain development
partners. Forward-looking statements involve inherent risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements as a result of various
factors including, among others: the ability to raise additional
capital in order to continue as a going concern; the ability to
obtain regulatory approvals necessary to sell ENDRA medical devices
in certain markets in a timely manner, or at all; the ability to
develop a commercially feasible technology and its dependence on
third parties to design and manufacture its products; the impact of
COVID-19 on ENDRA’s business plans; the ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission. You should
not rely upon forward-looking statements as predictions of future
events. The forward-looking statements made in this press release
speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230607005047/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com
Investor Relations Contact: Yvonne Briggs LHA Investor
Relations (310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
過去 株価チャート
から 4 2024 まで 5 2024
ENDRA Life Sciences (NASDAQ:NDRA)
過去 株価チャート
から 5 2023 まで 5 2024